Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027997 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
A Phase 2 study, sponsored by Addex Pharma S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05027997: Completed Phase 2 study, sponsored by Addex Pharma S.A..
NCT05027997 is a Phase 2 study that has completed, run by Addex Pharma S.A.. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05027997, a Phase 2 study, has completed, sponsored by Addex Pharma S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.
Primary Outcome
The primary outcome will be testing the safety and tolerability of dipraglurant in patients with blepharospasm based on the incidence of adverse events reported by patients and/or as identified by the Investigator based on clinical assessments conducted during the study.
Interventions
- DRUG Placebo
- DRUG Dipraglurant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-11-27 |
| Phase | Phase 2 |
What the finished NCT05027997 record still lists
NCT05027997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05027997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05027997 about?
NCT05027997 is a clinical study titled "Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm". This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency ...
What is the current status of trial NCT05027997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-10-06. Estimated completion is 2022-11-27.
What interventions are being tested in trial NCT05027997?
The interventions under investigation include: Placebo (DRUG), Dipraglurant (DRUG).
Who is sponsoring clinical trial NCT05027997?
This trial is sponsored by Addex Pharma S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05027997's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI